Yury Kukushkin

Investment Partner

2023 - Current

Managing Director

2022 - 2023

Investment Director

2019 - 2022

The T1D Fund is the first scale, mission-driven venture philanthropy fund focused on equity investments in companies developing life-changing T1D products. The T1D Fund has made investments in over 30 early-stage innovative companies with T1D programs and has attracted more than $600 million of additional private venture capital to these programs. The fund has grown to become one of the largest and most impact disease-focused venture philanthropy funds in the world with $175 million in assets under management.

Board Observer

2022 - 2023

Established in early 2020, as a spin-out of Institut Curie, Egle Therapeutics develops First-In-Class immunotherapies targeting immune suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases. The key element of Egle’s core approach is the leveraging of its translational-based target discovery platform to unveil novel therapeutic Treg targets and computationally designed immunocytokines acting as antagonists or as selective Treg-agonists. www.egle-tx.com

Board Observer

2022 - 2023

Inversago Pharma is a clinical-stage biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as diabetic nephropathy, Non-Alcoholic Steatohepatitis (NASH), complications of obesity, hypertriglyceridemia (HTG), Type 1 Diabetes (T1D) and Prader-Willi Syndrome (PWS), as well as fibrotic indications such as Progressive Fibrosis - Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF).

Board Observer

2021 - 2023

Code Bio is a biotechnology company pioneering targeted non-viral gene therapies as treatments and potential cures for serious and life-threatening genetic diseases

Board Observer +1

2020 - 2023

The company is developing first-in-class small molecule 12-LOX inhibitors that treat the underlying pathologies of thrombosis and type 1 diabetes.

Board Observer

2020 - 2023

IMT is the first company to target the root cause of autoimmunity with therapeutic design directed at HLA variants known to confer high disease risk. The Company platform builds drug molecules for specific blockade of an HLA protein in a given autoimmune disease as a novel paradigm in drug development.

Venture Partner

2019 - 2023

Principal

2016 - 2019

• Analysed over 150+ public companies and created a portfolio of 17 advanced therapy companies • Provided non-discretionary advice to sophisticated overseas investors in biotech • Analyzed over 400+ private companies. Key private deals closed: Investment in Retrosense, an optogenetics company with a product to treat terminally blind RP patients (sold to Allergan for $550+M) and Orchard therapeutics, a rare disease gene therapy company

Co-founder

2012 - 2017

Member of the Future Biotech 2012 summer school and 2013 winter school organizing committee

Associate

2013 - 2015

• Sourced companies to invest in (the UK, EU, and the USA), 300+ projects analyzed, $5M investments in two companies in the U.S. and UK. • Established valuation models for different types of biomedical companies